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Simple Summary: Cetuximab is an antibody that blocks EGFR signaling and stimulates an immune
response against cancer cells. For patients with advanced colorectal cancer, tumor sidedness and
RAS mutation status are the primary factors used to select systemic therapy. Additional biomarkers
are needed to better predict which patients will benefit from cetuximab-based regimens. The aim
of our retrospective study was to assess the predictive and prognostic value of 12 germline single
nucleotide polymorphisms in five immune related genes in 924 patients with advanced colorectal
cancer undergoing therapy with cetuximab. We identified a CD24 germline genetic variant which
independently predicted survival in a discovery cohort and confirmed these findings in a validation
cohort. If confirmed in prospective studies, CD24 and other immune related polymorphisms may
guide the use of cetuximab in patients with advanced colorectal cancer.
Abstract: Cetuximab, an IgG1 EGFR-directed antibody, promotes antibody-dependent cell-mediated
cytotoxicity. We hypothesized that single-nucleotide polymorphisms (SNPs) in immune regulatory
pathways may predict outcomes in patients with metastatic colorectal cancer treated with cetuximab-based
regimens. A total of 924 patients were included: 105 received cetuximab in IMCL-0144 and
cetuximab/irinotecan in GONO-ASL608LIOM01 (training cohort), 225 FOLFIRI/cetuximab in FIRE-3
(validation cohort 1), 74 oxaliplatin/cetuximab regimens in JACCRO CC-05/06 (validation cohort 2),
and 520 FOLFIRI/bevacizumab in FIRE-3 and TRIBE (control cohorts). Twelve SNPs in five genes (IDO1;
PD-L1; PD-1; CTLA-4; CD24) were evaluated by PCR-based direct sequencing. We analyzed associations
between genotype and clinical outcomes. In the training cohort; patients with the CD24 rs52812045 A/A
genotype had a significantly shorter median PFS and OS than those with the G/G genotype (PFS 1.3
vs. 3.6 months; OS 2.3 vs. 7.8 months) in univariate (PFS HR 3.62; p = 0.001; OS HR 3.27; p = 0.0004)
and multivariate (PFS HR 3.18; p = 0.009; OS HR 4.93; p = 0.001) analyses. Similarly; any A allele
carriers in the JACCRO validation cohort had a significantly shorter PFS than G/G carriers (9.2 vs.
11.8 months; univariate HR 1.90; p = 0.011; multivariate HR 2.12; p = 0.018). These associations
were not demonstrated in the control cohorts. CD24 genetic variants may help select patients with
metastatic colorectal cancer most likely to benefit from cetuximab-based therapy.
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1. Introduction
Cetuximab monotherapy and combinations with FOLFIRI (leucovorin, fluorouracil, irinotecan) or
FOLFOX (leucovorin, fluorouracil, oxaliplatin) have prolonged the survival of metastatic colorectal
cancer (mCRC) patients with RAS wild-type tumors [1,2]. Nonetheless, one-third of RAS-selected
patients do not benefit from cetuximab-based regimens [3], and treatment resistance develops
independent of RAS/RAF/MEK signaling.
Cetuximab, a chimeric IgG1 monoclonal antibody against the epidermal growth factor receptor
(EGFR), promotes antibody-dependent cell-mediated cytotoxicity (ADCC) [4,5]. Upon binding to the
FCγ receptor on natural killer (NK) and other immune cells, cetuximab facilitates Fas-FasL-induced
tumor cell apoptosis. In response to cetuximab-mediated ADCC, compensatory immunosuppressive
pathways (e.g., PDL-1, CTLA-4) may be activated by cancer cells [6]. While extended RAS testing
accounts for compensatory pathways that renders tumors resistant to cetuximab-mediated EGFR
inhibition [3], there are no validated markers to predict the benefit from its ADCC-dependent mode of
action. Identifying such markers could refine patient selection and reveal novel actionable alterations.
We previously demonstrated the prognostic value of FCγ-receptor polymorphisms in mCRC
patients receiving cetuximab [7]. With the advent of immune checkpoint inhibitors in mCRC,
identifying relevant biomarkers is an area of active investigation. We hypothesized that single
nucleotide polymorphisms (SNPs) within critical immune regulatory pathways may serve as clinically
meaningful markers in mCRC patients receiving cetuximab-based therapy. We examined 12 SNPs in
five genes (CD24, IDO1, PD-L1, PD-1, CTLA-4) to identify predictive and prognostic genetic variants in
a training cohort of mCRC patients treated with cetuximab with or without irinotecan in two phase
2 studies [8]. Then, we tested SNPs with significant prognostic associations in two validation cohorts
of mCRC patients, one treated with FOLFIRI-cetuximab in FIRE-3 [2] and the other treated with
oxaliplatin-cetuximab regimens in JACCRO CC-05/06. Lastly, we examined these associations in two
control cohorts who received FOLFIRI-bevacizumab in FIRE-3 and TRIBE [2,9].
2. Results
Patient baseline characteristics and primary outcome data are summarized in Table 1. Patients
in the training cohort had relatively refractory disease, with lower overall response rate (RR) (20.0%;
p < 0.001) and disease control rate (61.9%; p < 0.001), and an expectedly shorter median PFS (3.7 months,
95% CI: 3.2, 4.9 months; p < 0.001) and OS (10.6 months, 95% CI: 7.8, 13.2 months; p < 0.001) than those
in the validation or control cohorts who underwent first-line therapy.
Table 1. Baseline patient and tumor characteristics.
Characteristic
Training
Cohort
(N = 105)
FIRE-3
Validation
Cohort 1
(N = 225)
Japanese
Validation
Cohort 2
(N = 74)
FIRE-3
Control
Cohort 1
(N = 292)
TRIBE
Control
Cohort 2
(N = 228)
p-Value *
Age, years
Median (range) 63 (35–83) 64 (38–79) 63 (40-79) 65 (31-76) 60 (29–75) <0.001
Sex
Male 62 (59%) 159 (71%) 42 (57%) 194 (66%) 138 (61%) 0.059
Female 43 (41%) 66 (29%) 32 (43%) 98 (34%) 90 (39%)
Overall Response
Rate (ORR) 20.0% 61.3% 71.6% 57.2% 56.6% <0.001
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Table 1. Cont.
Characteristic
Training
Cohort
(N = 105)
FIRE-3
Validation
Cohort 1
(N = 225)
Japanese
Validation
Cohort 2
(N = 74)
FIRE-3
Control
Cohort 1
(N = 292)
TRIBE
Control
Cohort 2
(N = 228)
p-Value *
Disease Control Rate
(DCR) 61.9% 80.0% 91.9% 83.2% 89.0% <0.001
Median PFS, months
**
(95% CI)
3.7
(3.2–4.9)
9.8
(8·7–10.8)
10.0
(8.9–13.7)
10.1
(9.6–11.2)
9·7
(9.2–10.8) <0.001
Median OS, months
**
(95% CI)
10.6
(7.8–13.2)
28.6
(23.7–36.3)
33.9
(26.5+)
23.7
(21.4–26.4)
26.1
(22.7-30.9) <0.001
* p-value was based on the Kruskal-Wallis test for age, chi-square test for categorical variables, and log-rank test for
PFS and OS. ** Median follow-up was 18.2 months (range: 1.2–42.4 months), 35.3 months (range: 0.0–70.7 months),
31.0 months (range: 5.4–42.9 months), 40.7 months (range: 0.0–69.7 months), and 33.5 months (range: 2.8–53.2
months) in the training, validation 1, validation 2, FIRE-3 control, and TRIBE control cohorts, respectively.
2.1. Gene Variants and OS
Within the training cohort, three polymorphisms (CD24 rs52812045, IDO1 rs3739319, IDO1
rs9657182) were significantly associated with OS.
In the univariable analysis, patients in the training cohort with the CD24 rs52812045 G/A genotype
had a superior median OS relative to those with either homozygous genotype (G/A 13.1 vs. G/G 7.8
vs. A/A 2.3 months, HR 0.58, p < 0.001; Table 2, Figure 1A). This association held significance in a
multivariable model accounting for sex, age, ethnicity, and presence of rash (HR 0.50, 95% CI: 0.28–0.88,
p = 0.001; Table 2). There were no significant associations between CD24 rs52812045 and OS in the
validation (Tables 3 and 4) or control (Tables 5 and 6) cohorts.
Patients in the training cohort carrying the IDO1 rs3739319 G/G variant had a significantly longer
median OS (17.9 months) compared to those with the A/A (10.8 months, HR 2.13, 95% CI: 1.04–4.36) or
A/G (8.7 months, HR 2.12, 95% CI: 1.15–3.93) genotypes (p = 0.028; Table 2, Figure 1B). This association
held significance in multivariable analysis (p = 0.043). There were no significant associations between
IDO1 rs3739319 genotype and OS in the other cohorts. In the FIRE-3 validation cohort, patients with
an IDO1 rs3739319 A allele had a numerically longer OS (33.1 months) in univariate (HR 0.72, 95%
CI: 0.50–1.03, p = 0.068) and multivariate (HR 0.70, 95% CI: 0.48–1.02, p = 0.063) analyses, though this
association did not reach statistical significance (Table 3).
Patients in the training cohort with the IDO1 rs9657182 C/T (15.0 months, HR 0.49, 95% CI:
0.27–0.89) genotype had a significantly longer OS than those harboring the C/C genotype (8.5 months)
(p = 0.021; Table 2, Figure 1C). This relationship remained significant in multivariable analysis (p = 0.008;
Table 2). Conversely, in the Japanese validation cohort, patients with the heterozygote C/T genotype
had the shortest median OS (26.5 vs. 41.1+ months for C/C genotype; univariate HR 2.18, 95% CI
0.98–4.85), though with borderline significance (p = 0.049). There was a similar but non-significant
trend in multivariate analysis (p = 0.12) (Table 4). IDO1 rs9657182 genotype was not significantly
associated with OS in the other cohorts (Tables 3, 5 and 6).
Patients in the TRIBE control cohort with any PD-L1 rs2297137 A allele had a significantly
prolonged OS (33.9 months) compared to those with the G/G genotype (23.4 months) in univariable
(HR 0.63, 95% CI 0.45-0.89, p = 0.007) and multivariable analyses (HR 0.65, 95% CI 0.45–0.94, p = 0.021)
(Table S6). This association was not seen in the other cohorts.
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Figure 1. Kaplan-Meier plots according to genotype and outcome in the training cohort. (A) Overall 
survival (OS) stratified by CD24 rs52812045 genotype; (B) OS stratified by IDO1 rs3739319 genotype; 
(C) OS stratified by IDO1 rs9657182 genotype; (D) progression-free survival stratified by CD24 
rs52812045 genotype.
Figure 1. aplan- eier plots according to genotype and outco e in the training cohort. ( ) verall
survival ( S) stratified by 24 rs52812045 genotype; ( ) S stratified by I 1 rs3739319 genotype;
( ) S stratifie by I 1 rs9657182 ge oty e; ( ) rogressio -free s rvival stratifie by 24
rs e t e.
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Table 2. Immune regulatory single nucleotide polymorphisms (SNPs) and outcomes in patients with advanced colorectal cancer (CRC) treated with cetuximab-based
therapy (training cohort, Italian + USC).
SNP Tumor Response Progression-Free Survival Overall Survival
N PR SD + PD Median, ms(95% CI)
Univariable HR
(95% CI) †
Multivariable HR
(95% CI) ‡
Median, ms
(95% CI)
Univariable HR
(95% CI) †
Multivariable HR
(95% CI) ‡
IDO1 rs9657182
C/C 25 3 (12%) 22 (88%) 3.3 (2.2, 4.4) 1 (reference) 1 (reference) 8.5 (5.1, 10.8) 1 (reference) 1 (reference)
C/T 55 11 (20%) 43 (80%) 4.6 (3.4, 5.7) 0.77 (0.47, 1.26) 0.71 (0.42, 1.19) 15.0 (7.8, 15.9) 0.49 (0.27, 0.89) 0.39 (0.20, 0.74)
T/T 24 7 (30%) 16 (70%) 4.1 (2.4, 7.4) 0.56 (0.30, 1.04) 0.47 (0.25, 0.89) 12.0 (5.7, 20.4) 0.54 (0.27, 1.07) 0.38 (0.18, 0.79)
p-value * 0.33 0.13 0.068 0.021 0.008
IDO1 rs3739319
G/G 27 8 (31%) 18 (69%) 5.2 (4.0, 8.0) 1 (reference) 1 (reference) 17.9 (8.5, 26.4) 1 (reference) 1 (reference)
A/G 51 9 (18%) 41 (82%) 3.6 (2.5, 5.2) 1.35 (0.82, 2.23) 1.55 (0.92, 2.60) 8.7 (6.3, 12.0) 2.12 (1.15, 3.93) 2.32 (1.20, 4.50)
A/A 27 4 (15%) 23 (85%) 2.8 (2.4, 4.7) 1.72 (0.97, 3.08) 1.55 (0.83, 2.88) 10.8 (4.4, 15.0) 2.13 (1.04, 4.36) 2.06 (0.95, 4.47)
p-value * 0.32 0.15 0.22 0.028 0.043
CD24 rs52812045
G/G 54 8 (15%) 45 (85%) 3.6 (2.5, 4.6) 1 (reference) 1 (reference) 7.8 (5.7, 10.5) 1 (reference) 1 (reference)
G/A 36 10 (29%) 25 (71%) 5.0 (3.3, 6.6) 0.74 (0.47, 1.16) 0.62 (0.39, 1.00) 13.1 (8.7, 17.9) 0.58 (0.34, 0.99) 0.50 (0.28, 0.88)
A/A 5 0 (%) 5 (100%) 1.3 (1.0, 3.3) 3.62 (1.35, 9.70) 3.18 (1.10, 9.20) 2.3 (1.8, 11.3) 3.27 (1.23, 8.68) 4.93 (1.65, 14.77)
p-value * 0.20 0.001 0.009 <0.001 0.001
* p-value was based on Fisher’s exact test for response, log-rank test for PFS and OS in the univariate analysis (†), and Wald test for PFS and OS in the multivariable Cox regression model
(‡) that was adjusted for sex, age, rash, and racial background.
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Table 3. Immune regulatory SNPs and outcomes in patients receiving first-line FOLFIRI and cetuximab in FIRE-3 (validation cohort 1).
SNP Tumor Response Progression-Free Survival Overall Survival
N PR PD + SD Median, ms(95% CI)
Univariable HR
(95% CI)
Multivariable HR
(95% CI)
Median, ms
(95% CI)
Univariable HR
(95% CI)
Multivariable HR
(95% CI)
IDO1 rs9657182
C/C 63 39 (70%) 17 (30%) 9.6 (8.2, 13.0) 1 (reference) 1 (reference) 28.7 (16.8, 38.3) 1 (reference) 1 (reference)
C/T 86 48 (70%) 21 (30%) 9.7 (6.9, 11.3) 1.18 (0.83, 1.69) 1.09 (0.74, 1.61) 25.2 (22.6, 33.6) 1.15 (0.75, 1.76) 0.90 (0.56, 1.43)
T/T 72 49 (73%) 18 (27%) 10.0 (7.9, 11.5) 1.06 (0.74, 1.54) 1.13 (0.76, 1.68) 36.6 (21.3, 52.0) 0.84 (0.53, 1.32) 0.73 (0.45, 1.17)
p-value * 0.88 0.64 0.83 0.34 0.41
C/T or T/T 158 97 (71%) 39 (29%) 10.0 (8.2, 10.9) 1.12 (0.81, 1.55) 1.11 (0.78, 1.57) 28.0 (23.7, 37.5) 0.99 (0.67, 1.45) 0.81 (0.54, 1.22)
p-value * 0.86 0.48 0.56 0.96 0.32
IDO1 rs3739319
G/G 94 54 (69%) 24 (31%) 9.2 (7.9, 10.6) 1 (reference) 1 (reference) 23.9 (20.6, 36.6) 1 (reference) 1 (reference)
G/A 78 50 (69%) 22 (31%) 10.3 (7.8, 12.6) 0.81 (0.59, 1.12) 0.68 (0.48, 0.97) 30.6 (22.6, 49.8) 0.83 (0.56, 1.23) 0.75 (0.49, 1.16)
A/A 46 29 (74%) 10 (26%) 12.1 (8.7, 14.1) 0.68 (0.46, 1.00) 0.67 (0.45, 0.99) 38.7 (27.9, 68.7) 0.57 (0.35, 0.94) 0.61 (0.36, 1.04)
p-value * 0.88 0.12 0.040 0.079 0.14
G/A or A/A 124 79 (71%) 32 (29%) 10.5 (8.8, 12.6) 0.76 (0.57, 1.02) 0.67 (0.50, 0.91) 33.1 (27.6, 41.2) 0.72 (0.50, 1.03) 0.70 (0.48, 1.02)
p-value * 0.87 0.059 0.011 0.068 0.063
CD24 rs52812045
G/G 137 84 (72%) 33 (28%) 9.3 (7.9, 10.6) 1 (reference) 1 (reference) 25.2 (20.6, 33.4) 1 (reference) 1 (reference)
G/A 66 43 (68%) 20 (32%) 10.4 (8.0, 12.3) 0.92 (0.67, 1.27) 1.01 (0.72, 1.44) 33.8 (24.5, 40.0) 0.79 (0.53, 1.18) 0.61 (0.38, 0.97)
A/A 11 4 (57%) 3 (43%) 14.1 (5.7, 19.9) 0.61 (0.32, 1.17) 0.54 (0.26, 1.11) 41.2 (19.9, 56.2) 0.72 (0.33, 1.56) 1.15 (0.50, 2.65)
p-value * 0.56 0.31 0.24 0.40 0.093
G/A or A/A 77 47 (67%) 23 (33%) 11.3 (9.0, 12.8) 0.86 (0.64, 1.16) 0.90 (0.65, 1.25) 37.5 (26.5, 41.2) 0.77 (0.53, 1.13) 0.68 (0.44, 1.04)
p-value * 0.51 0.32 0.55 0.18 0.074
* p-value was based on Fisher’s exact test for tumor response, log-rank test for PFS and OS in the univariable analysis, and Wald test in the multivariable Cox proportional hazards
regression model adjusting for sex, primary tumor site, liver metastases, number of metastatic sites, LDH, Kohne score, RAS and BRAF mutation status.
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Table 4. Immune regulatory SNPs and outcomes in Japanese patients receiving first-line cetuximab plus oxaliplatin-based therapy (validation cohort 2).
SNP Tumor Response Progression-Free Survival Overall Survival
N PR SD + PD Median, ms(95% CI)
Univariable HR
(95% CI) †
Multivariable HR
(95% CI) ‡
Median, ms
(95% CI)
Univariable HR
(95% CI) †
Multivariable HR
(95% CI) ‡
IDO1 rs9657182
C/C 26 19 (79%) 5 (21%) 11.6 (9.2, 15.2) 1 (reference) 1 (reference) 41.1+ (17.9,41.1+) 1 (reference) 1 (reference)
C/T 30 19 (68%) 9 (32%) 9.5 (5.6, 13.8) 1.14 (0.63, 2.06) 1.11 (0.61, 2.04) 26.5 (18.4, 36.2) 2.18 (0.98, 4.85) 1.98 (0.86, 4.56)
T/T 16 13 (81%) 3 (19%) 9.1 (5.1, 16.7) 1.35 (0.66, 2.76) 1.21 (0.57, 2.55) 42.9+ (27.1,42.9+) 0.92 (0.33, 2.58) 0.87 (0.31, 2.47)
p-value * 0.63 0.68 0.88 0.049 0.12
C/T or T/T 46 32 (73%) 12 (27%) 9.5 (8.0, 13.6) 1.21 (0.70, 2.07) 1.14 (0.65, 2.00) 27.5 (23.2, 42.8) 1.64 (0.76, 3.52) 1.47 (0.66, 3.25)
p-value * 0.77 0.48 0.65 0.19 0.34
IDO1 rs3739319
G/G 22 17 (81%) 4 (19%) 10.0 (8.9, 15.2) 1 (reference) 1 (reference) 27.1 (16.0, 42.8) 1 (reference) 1 (reference)
G/A 34 21 (66%) 11 (34%) 9.1 (6.1, 11.8) 0.96 (0.52, 1.75) 0.98 (0.53, 1.81) 26.7 (18.4, 42.9) 0.98 (0.47, 2.05) 0.94 (0.45, 1.98)
A/A 16 13 (87%) 2 (13%) 13.6 (5.6, 15.2) 0.79 (0.37, 1.69) 0.75 (0.35, 1.64) 41.4+ (23.5,41.4+) 0.53 (0.20, 1.41) 0.51 (0.19, 1.39)
p-value * 0.27 0.80 0.73 0.35 0.38
G/A or A/A 50 34 (72%) 13 (28%) 9.7 (8.0, 13.8) 0.90 (0.51, 1.59) 0.91 (0.51, 1.62) 36.2 (21.5, 42.9) 0.80 (0.40, 1.61) 0.78 (0.39, 1.58)
p-value * 0.55 0.71 0.74 0.52 0.49
CD24 rs52812045
G/G 34 23 (74%) 8 (26%) 11.8 (9.4, 18.9) 1 (reference) 1 (reference) 33.9 (19.0, 39.6) 1 (reference) 1 (reference)
G/A a 28 21 (78%) 6 (22%) 9.2 (6.7, 13.8) 1.90 (1.05, 3.42) 2.12 (1.14, 3.95) 36.2 (23.5, 42.9) 0.88 (0.44, 1.76) 0.85 (0.41, 1.76)
A/A a 6 5 (83%) 1 (17%)
p-value * 1.00 0.011 0.018 0.71 0.66
* p-value was based on Fisher’s exact test for response, log-rank test for PFS and OS in the univariable analysis (†), and Wald test for PFS and OS in the multivariable Cox regression model
(‡) adjusting for ECOG performance status (0 vs. 1), and chemo backbone (FOLFOX vs. SOX). a Grouped together to estimate hazard ratios.
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Table 5. Immune regulatory SNPs and outcomes in patients treated with first-line FOLFIRI and bevacizumab in FIRE-3 (control cohort 1).
SNP Tumor Response Progression-Free Survival Overall Survival
N PR SD + PD Median, ms(95% CI)
Univariable HR
(95% CI) †
Multivariable HR
(95% CI) ‡
Median, ms
(95% CI)
Univariable HR
(95% CI) †
Multivariable HR
(95% CI) ‡
IDO1 rs9657182
C/C 76 47 (66%) 24 (34%) 13.2 (10.4,13.9) 1 (reference) 1 (reference) 26.4 (21.3, 32.8) 1 (reference) 1 (reference)
C/T 112 65 (62%) 40 (38%) 9.2 (8.6, 10.5) 1.61 (1.17, 2.22) 1.58 (1.12, 2.21) 22.1 (18.4, 26.3) 1.28 (0.89, 1.83) 1.28 (0.88, 1.87)
T/T 74 39 (57%) 29 (43%) 10.1 (8.8, 11.8) 1.26 (0.89, 1.79) 1.29 (0.90, 1.85) 24.8 (20.6, 29.1) 0.98 (0.66, 1.46) 1.21 (0.81, 1.82)
p-value * 0.58 0.010 0.031 0.22 0.42
C/T or T/T 186 104(60%) 69 (40%) 9.8 (8.9, 10.5) 1.45 (1.08, 1.95) 1.44 (1.06, 1.96) 23.1 (20.1, 26.7) 1.14 (0.82, 1.59) 1.25 (0.89, 1.76)
p-value * 0.39 0.010 0.019 0.43 0.20
IDO1 rs3739319
G/G 94 51 (61%) 33 (39%) 9.9 (8.6, 11.5) 1 (reference) 1 (reference) 21.9 (17.5, 25.6) 1 (reference) 1 (reference)
G/A 129 75 (62%) 46 (38%) 9.7 (8.8, 11.3) 0.87 (0.65, 1.16) 0.85 (0.63, 1.15) 25.0 (21.5, 28.4) 0.89 (0.64, 1.22) 0.87 (0.62, 1.22)
A/A 47 30 (68%) 14 (32%) 11.9 (9.8, 14.1) 0.75 (0.52, 1.10) 0.80 (0.54, 1.18) 27.6 (18.5, 35.0) 0.82 (0.53, 1.25) 0.89 (0.57, 1.38)
p-value * 0.72 0.30 0.43 0.59 0.71
G/A or A/A 176 105(64%) 60 (36%) 10.3 (9.2, 11.8) 0.83 (0.63, 1.09) 0.83 (0.63, 1.10) 25.1 (22.3, 28.6) 0.87 (0.64, 1.17) 0.88 (0.64, 1.20)
p-value * 0.68 0.18 0.21 0.34 0.41
CD24 rs52812045
G/G 130 68 (56%) 53 (44%) 9.6 (8.8, 11.7) 1 (reference) 1 (reference) 23.7 (19.4, 27.4) 1 (reference) 1 (reference)
G/A a 129 79 (66%) 40 (34%) 10.5 (9.8, 12.4) 0.86 (0.66, 1.12) 0.77 (0.59, 1.02) 26.1 (21.5, 28.8) 1.01 (0.76, 1.35) 1.00 (0.74, 1.36)
A/A a 7 4 (57%) 3 (43%)
p-value * 0.25 0.25 0.068 0.93 0.98
* p-value was based on Fisher’s exact test for tumor response, log-rank test for PFS and OS in the univariable analysis (†), and Wald test in the multivariable Cox regression model (‡)
adjusting for sex, ECOG performance status, primary tumor resection, number of metastatic sites, adjuvant chemotherapy, LDH, RAS and BRAF mutation status. a Grouped together to
estimate hazard ratios.
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Table 6. Immune regulatory SNPs and outcomes in patients receiving first-line FOLFIRI and bevacizumab in TRIBE (control cohort 2).
SNP Tumor Response Progression-Free Survival Overall Survival
N PR SD + PD Median, ms(95% CI)
Univariable HR
(95% CI) †
Multivariable HR
(95% CI) ‡
Median, ms
(95% CI)
Univariable HR
(95% CI) †
Multivariable HR
(95% CI) ‡
IDO1 rs9657182
C/C 44 20 (49%) 21 (51%) 8.8 (7.8, 10.5) 1 (reference) 1 (reference) 23.6 (14.7, 33.9) 1 (reference) 1 (reference)
C/T 112 66 (61%) 42 (39%) 9.4 (8.6, 10.5) 0.82 (0.55, 1.22) 0.87 (0.57, 1.32) 25.6 (21.1, 28.6) 0.94 (0.64, 1.40) 0.99 (0.65, 1.49)
T/T 65 38(58%) 27(42%) 11.3 (9.6, 12.7) 0.67 (0.44, 1.04) 0.70 (0.45, 1.11) 30.9 (22.7, 39.7) 0.74 (0.48, 1.14) 0.74 (0.47, 1.16)
p-value * 0.40 0.18 0.29 0.28 0.24
A/G or G/G 177 104(60%) 69 (40%) 10.3 (9.3, 11.1) 0.76 (0.52, 1.10) 0.80 (0.54, 1.19) 26.2 (22.7, 30.8) 0.86 (0.59, 1.25) 0.88 (0.60, 1.30)
p-value * 0.22 0.14 0.27 0.42 0.52
IDO1 rs3739319
G/G 78 45 (60%) 30 (40%) 11.1 (8.3, 12.3) 1 (reference) 1 (reference) 23.9 (19.4, 28.7) 1 (reference) 1 (reference)
G/A 90 44 (50%) 44 (50%) 9.4 (8.7, 10.4) 1.19 (0.84, 1.69) 1.25 (0.87, 1.80) 26.5 (22.0, 33.0) 0.82 (0.59, 1.16) 0.84 (0.59, 1.20)
A/A 48 33 (70%) 14 (30%) 9.7 (8.6, 10.8) 1.01 (0.67, 1.55) 1.12 (0.71, 1.76) 29.2 (19.6, 39.2) 0.71 (0.47, 1.08) 0.80 (0.52, 1.23)
p-value * 0.070 0.55 0.48 0.25 0.50
G/A or A/A 138 77 (57%) 58 (43%) 9.5 (9.0, 10.4) 1.13 (0.82, 1.55) 1.20 (0.87, 1.67) 27.4 (23.9, 33.6) 0.78 (0.57, 1.07) 0.83 (0.60, 1.14)
p-value * 0.77 0.45 0.27 0.12 0.24
CD24 rs52812045
G/G 123 71 (59%) 49 (41%) 9.5 (8.8, 10.8) 1 (reference) 1 (reference) 28.7 (23.9, 35.1) 1 (reference) 1 (reference)
G/A 79 42 (55%) 34 (45%) 9.9 (9.3, 12.6) 0.98 (0.71, 1.35) 0.78 (0.55, 1.10) 24.0 (20.3, 27.3) 1.30 (0.94, 1.79) 1.38 (0.99, 1.94)
A/A 21 13 (62%) 8 (38%) 9.2 (6.7, 11.3) 1.22 (0.71, 2.11) 1.00 (0.56, 1.79) 22.3 (15.6, 48.7) 1.17 (0.70, 1.97) 1.34 (0.78, 2.30)
p-value * 0.82 0.73 0.35 0.27 0.14
G/A or A/A 100 55 (57%) 42 (43%) 9.7 (9.2, 11.6) 1.02 (0.75, 1.38) 0.82 (0.59, 1.13) 23.5 (20.3, 27.3) 1.27 (0.94, 1.71) 1.38 (1.00, 1.89)
p-value * 0.78 0.91 0.22 0.11 0.049
* p-value was based on Fisher’s exact test for tumor response, log-rank test for PFS and OS in the univariable analysis (†), and Wald test in the multivariable Cox proportional
hazards regression model (‡) adjusting for sex, age, ECOG performance status, primary tumor site, number of metastatic sites, BRAF mutation status, resection of the primary tumors,
and adjuvant therapy.
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2.2. Gene Variants and PFS
One polymorphism (CD24 rs52812045) was significantly associated with PFS in the training cohort.
In the training cohort, the CD24 rs52812045 A/A genotype was associated with shorter median
PFS (1.3 months) in both univariable (HR 3.62, 95% CI: 1.35–9.70, p = 0.001) and multivariable analyses
(HR 3.18, 95% CI: 1.10–9.20, p = 0.009) (Table 2, Figure 1D). Similarly, in the Japanese validation cohort,
the A allele was associated with significantly shorter PFS in univariable (HR 1.90, 95% CI: 1.05–3.42,
p = 0.011) and multivariable (HR 2.12, 95% CI: 1.14–3.95, p = 0.018) analyses (Table 4). There were no
significant associations between CD24 rs52812045 and PFS in the other cohorts (Tables 3, 5 and 6).
In the FIRE-3 control cohort, patients harboring a T allele of IDO1 rs9657182 had a significantly
shorter PFS (9.8 months) compared to those with the C/C genotype (13.2 months) in univariable
(HR 1.45, 95% CI: 1.08–1.95, p = 0.010) and multivariable analyses (HR 1.44, 95% CI: 1.06–1.96, p = 0.019)
(Table 5). This association was not demonstrated in the other cohorts.
Patients in the FIRE-3 validation cohort with any A allele of IDO1 rs3739319 achieved a prolonged
PFS compared to those with the G/G genotype, but only in multivariable analysis (10.5 vs. 9.2 months;
univariable HR 0.76, 95% CI: 0.57–1.02, p = 0.059; multivariable HR 0.67, 95% CI: 0.50–0.91, p = 0.011)
(Table 3). This trend was not evident in the other cohorts.
Patients in the training cohort with the CTLA4 rs231777 C/T genotype had a significantly shorter
PFS (2.6 months) compared to those with the C/C variant (4.1 months), but only in multivariable
analysis (HR 1.76, 95% CI: 1.10–2.81, p = 0.019) (Table S2). This association was not seen in the
other cohorts.
2.3. Gene Variants and Tumor Response
In the training cohort, patients with the PD-L1 rs2297137 A/A genotype demonstrated a greater
RR (56%) than patients with G/A (19%) or G/G (16%) genotypes (two-sided Fisher’s exact test
p = 0.029) (Table S2). There was no association between PD-L1 genotype and RR in the validation or
control cohorts.
3. Discussion
Cetuximab affects EGFR inhibition as well as innate and adaptive immunity [10–13]. While RAS
mutation status is a validated predictive marker for cetuximab in mCRC patients, it may not completely
account for its immunomodulatory effects.
The wide-ranging immunogenic effects of cetuximab have been demonstrated in multiple
studies [6,10]. Cetuximab binds the Fc portion of the activating receptor on NK cells, which may lead
to direct cancer cell lysis and the release of tumor antigens which can be presented by dendritic cells to
cytotoxic T-cells [6]. Moreover, activated NK cells may use cytokines and interferon to activate tumor
suppressing macrophages [6]. In CRC cell lines and murine xenograft models, cetuximab has been
shown to induce immunogenic cell death, marked by increased phagocytosis by dendritic cells [10],
as well as stimulating and enhancing NK cell activity [14]. The cytotoxic agents, 5-FU and irinotecan,
have also been shown to improve the ADCC activity of cetuximab across different CRC cell lines, in part
by increasing cell surface EGFR expression [15]. The interaction between KRAS mutations and the
ability of cetuximab to mediate ADCC is not completely understood. Some studies have shown ADCC
to be dependent on KRAS-wildtype status [16], while others show the effects to be independent of KRAS
status [6]. In mCRC patients with liver-limited metastases undergoing pre-operative chemotherapy
with or without cetuximab, cetuximab was shown to increase the degree of tumor infiltration with
CD3+ and CD8+ T-cells in addition to CD56+ NK cells [11]. Clinically, the degree of ADCC activity
(as measured in peripheral blood mononuclear cells and by NK-dependent LDH release) has been
positively associated with improved survival [17], as well as degree of tumor shrinkage [18] in mCRC
patients receiving cetuximab.
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Much of the literature regarding the predictive and prognostic impact of immune-related
germline polymorphisms on cetuximab efficacy has focused on the FCγ-receptor family [7,19–21].
As immunotherapeutics become integrated into the management of advanced CRC, discovering
markers of efficacy within immune mediated pathways will become increasingly important. To our
knowledge, this is the first study to evaluate the predictive and prognostic utility of common genetic
variants within checkpoint and other immune regulatory pathways in mCRC patients receiving
cetuximab-based therapy.
CD24, a membrane surface glycosyl-phosphatidyl-inositol-(GPI)-anchored protein, is overexpressed
in 90% of colorectal tumors [22] and has been implicated in inflammatory bowel disease (IBD) [23,24]. As a
putative marker of EGF and Wnt-expressing metaplastic Paneth cells [25,26], CD24 provides a crucial link
between host mucosal immunity, colonic crypt homeostasis [27], and the intestinal stem cell niche [28,29].
Indeed, CD24 knockout mice models exhibit reduced T-cell proliferation [30], blunted polyp formation,
and suppressed colorectal tumorigenesis [22,31]. Furthermore, the effects of CD24 on ADCC and
chronic inflammation are thought to be partly mediated by autophagy [27,32], another purported
mechanism of cetuximab efficacy [33].
CD24 maps to chromosome 6q21 and rs52812045 is located in the GPI-anchor cleavage site [34].
Clinically, this polymorphism has been associated with pathologic complete response and concomitant
intra-tumoral lymphocyte infiltration in breast cancer patients [35,36], and poor prognosis in
esophageal cancer patients [37]. However, a recent meta-analysis of CD24 SNPs and cancer risk was
non-confirmatory [38]. In our study, carriers of the CD24 rs52812045 A/A variant in the training cohort
had the shortest PFS and OS compared to those with the G/G and G/A genotypes, with heterozygotes
appearing to have an OS advantage (albeit with the 95% CI boundary near 1 in univariable analysis).
Similarly, in the Japanese validation cohort, the A allele was associated with shorter PFS. It is
important to note that very few patients carried the A/A genotype which limits the power of the
analysis. In addition, patients in the training cohort received cetuximab monotherapy or cetuximab
combined with irinotecan, while patients in the Japanese cohort received cetuximab combined with a
fluoropyrimidine (5-FU or S-1) and oxaliplatin. Each cytotoxic agent has its own immunomodulatory
effects or may impact those seen with cetuximab, and this may have influenced our results. Nonetheless,
our findings warrant further evaluation. If confirmed in larger, prospective studies, CD24 rs52812045
genotype may be used to select mCRC patients most likely to benefit from cetuximab-based regimens
in clinical practice.
Another critical modulator of intestinal immunity and stem cell signaling is IDO1, an enzyme
which catalyzes the rate-limiting step of tryptophan catabolism within the kynurenine pathway [39].
Released by tumor and myeloid derived suppressor cells, IDO1 depletes T-cells of tryptophan, thereby
attenuating their activity [40]. Plasmacytoid dendritic cells express IDO1 to convert naïve T-cells into
Treg-cells and increase PD-L1/PD-L2 expression, leading to T-cell suppression [41,42]. Independent of
its immunoregulatory effects, IDO1 has been shown to activate canonical Wnt-β-catenin signaling and
promote tumor progression by decreasing the tryptophan/kynurenine ratio [43].
Clinically, IDO1 mRNA expression has been correlated with colitis severity [44], peri-tumoral
immune tolerance, and worse survival in CRC patients [45,46]. IDO1 genetic variants have been
associated with IBD severity [47], and we previously demonstrated the prognostic value of IDO1
rs3739319 in patients with liver-limited mCRC [48]. Consistent with prior findings, the IDO1 rs3739319
A allele was a negative prognosticator in our training cohort, though an opposite relationship
was observed in the FIRE-3 validation cohort. Notably, the IDO1 rs9657182 T allele conferred a
positive prognostic effect in patients receiving irinotecan-cetuximab in the training cohort, but a
negative effect in patients receiving oxaliplatin-cetuximab regimens in the Japanese validation
cohort, and bevacizumab-treated patients of the FIRE-3 control cohort. Similarly, PD-L1 rs2297137
predicted outcomes in both cetuximab and bevacizumab-treated patients. This may reflect the
immunomodulatory activity of bevacizumab [49] and suggests distinct roles for IDO1 and PD-L1 in
mediating these effects, which may vary by chemotherapy regimen.
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Our study has its limitations, the first being its retrospective nature. Prospective studies are
needed to further validate our findings in patients with mCRC receiving cetuximab-based therapy.
Clinical trials combining cetuximab with immune therapy and chemotherapy in patients with mCRC
are ongoing and incorporating the CD24 or IDO1 genotype as a stratification factor may guide the
use of these SNPs as predictive markers. Notably, there were certain genotypes that were carried by
a small number of patients, and this limited our ability to test combinations of alleles and limits the
strength of our conclusions. The heterogeneity of concomitant chemotherapy received between the
cohorts may have also impacted our results, and future studies controlling for this variable will be
important to translate the utility of these SNPs in the clinic. In addition, the RAS mutation status was
unknown for a proportion of patients. As the role of RAS signaling on cetuximab-mediated ADCC is
unclear [16,50–52], deciphering differential effects of these SNPs based on the RAS status could guide
future study design.
Studies examining the effect of these SNPs on gene function as well as associations between
genotype/haplotype and immune cell subsets, serum cytokine levels, PDL-1 status, tumor mutational
burden, and pathologic features (e.g., poor differentiation, tumor infiltrating lymphocytes, mucinous
histology) may provide mechanistic explanations for the observed findings and better characterize
the link between genotype and clinical outcomes. The presence of microsatellite instability (MSI) and
BRAF V600E mutations also affect the tumor immune milieu and may have influenced the relationship
between germline variants and outcomes; this information was not available in the present study.
Therefore, further investigations should evaluate the effect of MSI and BRAF mutation status (V600E
and perhaps non-V600E) on the predictive and prognostic utility of CD24 or IDO1 genotype, especially
as it pertains to the efficacy of immune therapy combinations [53]. For instance, avelumab is currently
being tested in combination with FOLFOXIRI plus cetuximab in the mCRC frontline setting in the phase
2 AVETRIC trial (NCT04513951). Others are examining the efficacy of first-line FOLFIRI plus cetuximab
in mCRC patients based on FCγ-receptor genotype in the phase 2 CIFRA trial (NCT03874026). Specific
germline polymorphisms or composite haplotypes, in conjunction with tumor features (e.g., sidedness)
and molecular profile (e.g., RAS, BRAF, HER2, MSI status, CMS subtype) may serve to inform the
selection of mCRC patients to treat with cetuximab and other targeted or immune therapies.
4. Materials and Methods
4.1. Study Design and Patient Population
A total of 924 mCRC patients with sufficient tissue for analysis were included in this study.
The training cohort consisted of 105 patients enrolled in two phase II clinical trials. Thirty-two patients
with EGFR-expressing mCRC refractory to irinotecan, oxaliplatin, and fluoropyrimidines were recruited
October 2002-March 2003, at the University of Southern California/Norris Comprehensive Cancer
Center (USC/NCCC) to the phase 2, open-label, multicenter ImClone-0144 (IMCL-0144) study [8],
and treated with single-agent cetuximab. The remaining 73 patients were recruited to a phase 2 trial
(protocol ASL608LIOM01) conducted by the Gruppo Oncologico Nord Ovest (EudraCT 2008-003160-19)
and received irinotecan-cetuximab.
Among the twelve SNPs tested in the training cohort, five (CD24 rs52812045, IDO1 rs9657182
and rs3739319, PDL1 rs2297137, CTLA4 rs231777) showed significant associations with response
rate (RR), progression-free survival (PFS), and/or overall survival (OS). These five SNPs were tested
in two independent validation and two independent control cohorts. The first validation cohort
consisted of 225 patients with KRAS exon 2 wildtype mCRC treated with FOLFIRI-cetuximab in
FIRE-3 (NCT00433927). FIRE-3 was a phase 3 trial randomizing patients with mCRC to first-line
FOLFIRI-cetuximab versus FOLFIRI-bevacizumab. The second validation cohort consisted of 74
patients enrolled in two phase 2 trials of first-line therapy with cetuximab-oxaliplatin-containing
chemotherapy, either mFOLFOX6 (JACCRO-CC-05; n = 57, UMIN000004197) or SOX (JACCRO-CC-06;
n = 67, UMIN000007022). Two control cohorts consisted of patients treated with FOLFIRI-bevacizumab
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in FIRE-3 (n = 292) and TRIBE (n = 228) (NCT00719797) [2,9]. TRIBE was a phase 3 trial randomizing
patients with mCRC to first-line FOLFOXIRI-bevacizumab versus FOLFIRI-bevacizumab. The KRAS
status was analyzed in 407 (80.1%) patients from TRIBE, of which 38.7% were wildtype in the
FOLFIRI-bevacizumab arm [9].
Eligible patients had stage 4 histologically confirmed colorectal adenocarcinoma, with measurable
disease per response evaluation criteria in solid tumors (RECIST) 1.0 criteria, and life expectancy of
≥12 weeks. Standard inclusion and exclusion criteria were applied. Treatment was administered until
disease progression, intolerable toxicities, or patient withdrawal. The current study was conducted
at the USC/NCCC and approved by the USC Institutional Review Board (HS-997018). All patients
signed informed consent for molecular correlates analysis. This study adheres to the reporting
recommendations for tumor MARKer prognostic studies (REMARK).
4.2. Candidate Single-Nucleotide Polymorphisms
Polymorphisms were selected based on a minimum allele frequency of 10% in Caucasians,
functional or predicted functional relevance of the respective gene or protein, TagSNP, and location.
Functional significance was predicted based on information derived from the National Institute of
Environmental Health Sciences SNP Function Prediction [54], and the Queen’s University F-SNP [55].
Selected polymorphisms are presented in Table S1.
4.3. Genotyping
Genotyping was performed on DNA extracted from whole blood or tissue samples using the
QIAamp Kit (Qiagen, Germantown, MD, USA), followed by PCR-based direct sequencing as previously
published [56,57]. All primers (Table S1) were validated on known DNA sequences. Sequencing results
were analyzed using the ABI Sequencing Scanner v1.0 (Applied Biosystems, Foster, CA, USA) by one
investigator (N.B.V.) blinded to the patients’ identifying data and outcomes.
4.4. Statistical Analyses
The primary endpoint of this retrospective correlative analysis was OS, defined as the period from
the randomization start date to death from any cause, or the date of last follow-up if patients were still
alive. The secondary endpoints included RR per RECIST 1.0 and PFS. PFS was defined as the period
from the randomization start date to first observation of tumor progression or death, whichever came
first. PFS was censored at the date of last follow-up if patients remained alive and progression-free.
Patients were compared between cohorts using the Kruskal-Wallis test for continuous variables,
chi-square test for categorical variables, and log-rank test for PFS and OS. Associations between
SNPs and clinical outcomes were tested in univariable and multivariable analyses. The log-rank
test and Kaplan-Meier curves were performed to investigate associations between SNPs and OS or
PFS in univariable analysis. Multivariable Cox proportional hazard regression models were used to
re-examine associations between SNPs and OS or PFS when adjusting for patient baseline characteristics.
Fisher’s exact test was used to test associations between SNPs and RR. SNPs without significant
associations with clinical outcomes are outlined in Tables S2–S6.
SAS 9.3 (SAS Institute, Cary, NC, USA) was used to perform all analyses. Case-wise deletion was
applied when patients with missing SNPs were excluded in the analyses. All tests were two-sided at a
significance level of 0.05.
5. Conclusions
Cetuximab is an established therapy for mCRC, which affects both EGFR signaling and ADCC.
As the role of immune checkpoint inhibition in mCRC is being actively defined, identifying biomarkers
of the immunomodulatory effects of cetuximab may refine its clinical use and inform the development
of chemo-immunotherapy combinations. We examined common genetic variants within immune
regulatory pathways and identified CD24 and IDO1 polymorphisms, which independently predicted
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outcomes. Further studies are needed to evaluate the functional relevance and clinical utility of these
genetic variants in patients with mCRC receiving cetuximab-based therapy.
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